Roivant Sciences Ltd. (NASDAQ:ROIV) Holdings Lifted by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. grew its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 27.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,079 shares of the company’s stock after buying an additional 1,507 shares during the period. PNC Financial Services Group Inc.’s holdings in Roivant Sciences were worth $84,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in ROIV. E Fund Management Co. Ltd. raised its stake in Roivant Sciences by 20.3% during the 4th quarter. E Fund Management Co. Ltd. now owns 50,647 shares of the company’s stock valued at $599,000 after acquiring an additional 8,535 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Roivant Sciences during the fourth quarter valued at $995,000. M&T Bank Corp raised its stake in shares of Roivant Sciences by 16.3% during the fourth quarter. M&T Bank Corp now owns 13,194 shares of the company’s stock valued at $156,000 after purchasing an additional 1,851 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in Roivant Sciences by 6.1% in the fourth quarter. Victory Capital Management Inc. now owns 27,494 shares of the company’s stock worth $325,000 after purchasing an additional 1,588 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Roivant Sciences by 1.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,812,502 shares of the company’s stock valued at $33,272,000 after buying an additional 45,090 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ROIV has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $17.10.

Roivant Sciences Trading Down 1.5 %

Shares of NASDAQ ROIV opened at $10.67 on Wednesday. Roivant Sciences Ltd. has a twelve month low of $9.96 and a twelve month high of $13.06. The firm has a 50-day moving average of $10.78 and a two-hundred day moving average of $11.44. The company has a market capitalization of $7.61 billion, a price-to-earnings ratio of -71.13 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, research analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Insider Activity

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the completion of the sale, the chief operating officer now directly owns 732,294 shares of the company’s stock, valued at approximately $8,260,276.32. This represents a 12.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now owns 163,264 shares in the company, valued at $1,702,843.52. This represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 2,439,640 shares of company stock worth $27,451,035. Insiders own 7.90% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.